The Rutgers Cancer Institute of New Jersey announced it has begun a clinical trial that will examine whether an anti-malaria drug doctors are administering as an off-label use to treat the coronavirus is more effective when taken with an antibiotic. Clinical trials take year to complete. But Rutgers, a nationally recognized comprehensive cancer center, has the in-house expertise to move faster, said Rutgers Cancer Institute Director Steven K. Libutti, who is overseeing the trial. To read the full article.
Recent Posts
- NJIT Students Develop Mental Health Side-Effect Tracker Recognized at Pfizer Hackathon.
- Older Adults With HIV May Be Facing Unequal Burden in the Opioid Crisis.
- Rutgers Medical Students Learn Importance of Humanity, Creativity and Connection in Patient-Centered Medicine.
- Artificial Intelligence Recreates the Motion of a Beating Heart Using Surface Electrical Recordings.
- Scientists Discover Potential Blood Test for Asthma Diagnosis and Severity.
Categories
- Community (2,364)
- Covid (992)
- CTO Events (6)
- News (3,001)
- Pilots (21)